

Epiomic Epidemiology Series: Leukaemia Forecast in 18 Major Markets 2017-2027

<https://marketpublishers.com/r/EF035B66787EN.html>

Date: December 2016

Pages: 82

Price: US\$ 6,150.00 (Single User License)

ID: EF035B66787EN

Abstracts

Multiple Sclerosis (MS) (also known as disseminated sclerosis) is a chronic, inflammatory demyelinating immune-mediated disease of the central nervous system (CNS). MS is characterised by the formation of lesions in the central nervous system, the destruction of the myelin sheath (insulation surrounding the nerve fibres of the CNS) and inflammation. Patients can exhibit a broad range of signs and symptoms associated with neural damage and dysfunction.

This report provides the current prevalent population for Multiple Sclerosis across 18 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Turkey, Australia, Poland, Romania, Russia, Mexico, Argentina, Brazil, Japan, India, China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Multiple Sclerosis have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Multiple Sclerosis include:

Osteoporosis

Osteopenia

Diabetes

Hyperlipidaemia

Hypertension

Uveitis

Muscle stiffness or spasms

Paralysis (typically of the legs)

Problems with the bladder/bowel/sexual function

Mental changes (forgetfulness/mood swings)

Depression

Epilepsy

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

Able to quantify patient populations in global Multiple Sclerosis market to target the development of future products, pricing strategies and launch plans.

Gain further insight into the prevalence of the subdivided types of Multiple Sclerosis and identify patient segments with high potential.

Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

Provide a level of understanding on the impact from specific co-morbid

conditions on Multiple Sclerosis prevalent population.

Identify sub-populations within Multiple Sclerosis which require treatment.

Gain an understanding of the specific markets that have the largest number of Multiple Sclerosis patients.

Contents

- Introduction
- Cause of the Disease
- Risk Factors & Prevention
- Diagnosis of the Disease
- Variation by Geography/Ethnicity
- Disease Prognosis & Clinical Course
- Key comorbid features associated with the disease
- Methodology for quantification of patient numbers
- Top-line Incidence for Leukaemia
- Type of Leukaemia
 - Lymphocytic Leukaemia
 - Acute Lymphocytic Leukaemia
 - Chronic Lymphocytic Leukaemia
 - Myeloid & Monocytic Leukaemia
 - Chronic Myeloid Leukaemia
 - Other Types of Leukaemia
- Treatment Rates
- Abbreviations used in the Report
- Other Black Swan Analysis Publications
- Black Swan Analysis Online Patient-Based Databases
- Patient-Based Offering
- Online Pricing Data and Platforms
- References
- Appendix

List Of Tables

LIST OF TABLES

The Rai staging system for CLL
CML Prognostic scores
Incidence of leukaemia, total (000s)
Incidence of leukaemia, males (000s)
Incidence of leukaemia, females (000s)
Type of Leukaemia, total (000s)
Type of Lymphocytic Leukaemia, total (000s)
Subtype of Acute lymphocytic Leukaemia, total (000s)
Philadelphia chromosome abnormality in ALL patients, total (000s)
CLL patients by Rai Stage, total (000s)
CLL patients with 17p Deletion, total (000s)
CLL patients with Haemolytic anaemia, total (000s)
Type of Myeloid/ Monocytic Leukaemia, total (000s)
Type of CML, total (000s)
Phase at Diagnosis of CML patients, total (000s)
CML patients by Sokal Risk Score, total (000s)
CML patients by Hasford Risk Score, total (000s)
Spleen size, total (000s)
Other Leukaemias, total (000s)
CLL treated patients by line of therapy, total (000s)
CML treated patients by line of therapy, total (000s)
Abbreviations and Acronyms used in the report
USA Incidence of Leukaemia by 5-yr age cohort, males (000s)
USA Incidence of Leukaemia by 5-yr age cohort, females (000s)
Canada Incidence of Leukaemia by 5-yr age cohort, males (000s)
Canada Incidence of Leukaemia by 5-yr age cohort, females (000s)
France Incidence of Leukaemia by 5-yr age cohort, males (000s)
France Incidence of Leukaemia by 5-yr age cohort, females (000s)
Germany Incidence of Leukaemia by 5-yr age cohort, males (000s)
Germany Incidence of Leukaemia by 5-yr age cohort, females (000s)
Italy Incidence of Leukaemia by 5-yr age cohort, males (000s)
Italy Incidence of Leukaemia by 5-yr age cohort, females (000s)
Spain Incidence of Leukaemia by 5-yr age cohort, males (000s)
Spain Incidence of Leukaemia by 5-yr age cohort, females (000s)
UK Incidence of Leukaemia by 5-yr age cohort, males (000s)

UK Incidence of Leukaemia by 5-yr age cohort, females (000s)
Brazil Incidence of Leukaemia by 5-yr age cohort, males (000s)
Brazil Incidence of Leukaemia by 5-yr age cohort, females (000s)
Japan Incidence of Leukaemia by 5-yr age cohort, males (000s)
Japan Incidence of Leukaemia by 5-yr age cohort, females (000s)
India Incidence of Leukaemia by 5-yr age cohort, males (000s)
India Incidence of Leukaemia by 5-yr age cohort, females (000s)
China Incidence of Leukaemia by 5-yr age cohort, males (000s)
China Incidence of Leukaemia by 5-yr age cohort, females (000s)
Turkey Incidence of Leukaemia by 5-yr age cohort, males (000s)
Turkey Incidence of Leukaemia by 5-yr age cohort, females (000s)
Australia Incidence of Leukaemia by 5-yr age cohort, males (000s)
Australia Incidence of Leukaemia by 5-yr age cohort, females (000s)
Mexico Incidence of Leukaemia by 5-yr age cohort, males (000s)
Mexico Incidence of Leukaemia by 5-yr age cohort, females (000s)
Argentina Incidence of Leukaemia by 5-yr age cohort, males (000s)
Argentina Incidence of Leukaemia by 5-yr age cohort, females (000s)
Russia Incidence of Leukaemia by 5-yr age cohort, males (000s)
Russia Incidence of Leukaemia by 5-yr age cohort, females (000s)
Saudi Arabia Incidence of Leukaemia by 5-yr age cohort, males (000s)
Saudi Arabia Incidence of Leukaemia by 5-yr age cohort, females (000s)
South Africa Incidence of Leukaemia by 5-yr age cohort, males (000s)
South Africa Incidence of Leukaemia by 5-yr age cohort, females (000s)

I would like to order

Product name: Epiomic Epidemiology Series: Leukaemia Forecast in 18 Major Markets 2017-2027

Product link: <https://marketpublishers.com/r/EF035B66787EN.html>

Price: US\$ 6,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/EF035B66787EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970